References in periodicals archive ?
Sold under the brand name Evista, raloxifene is used both to prevent and treat osteoporosis in post-menopausal women.
Because of its tissue selectivity, raloxifene may have fewer side effects than are typically observed with estrogen therapy including vaginal bleeding and breast tenderness.
Results: In the study cohort (N = 10,566), 12-month adherence/persistence rates were alendronate 61%/21%, risedronate 58%/19%, and raloxifene 54%/16%.
Researchers report that roughly the same number of women--167 and 163--developed breast cancer while taking raloxifene and tamoxifen, respectively.
But women given raloxifene daily and monitored for four years also had 36 per cent fewer uterine cancers and 29 per cent fewer blood clots than women taking tamoxifen.
Women given raloxifene daily, and who were followed for about four years, also had 36% fewer uterine cancers and 29% fewer blood clots than women taking tamoxifen.
National Cancer Institute (NCI) News Release "Initial Results of the Study of Tamoxifen and Raloxifene (STAR) Released: Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Breast Cancer", Monday, April 17, 2006
Both drugs are approved by the Federal Drug Administration, but researchers will study whether raloxifene can also serve a dual role.
This might be a fine time to talk about either hormone therapy or the use of a SERM such as raloxifene (Evista), which would help protect the bones you have right now.
It reported on a study published in JAMA indicating that raloxifene lessened the risk of heart attacks, strokes, and other cardiovascular events among postmenopausal women.